布地奈德混悬液治疗慢性阻塞性肺疾病临床研究(2)
参见附件(12kb)。
本组研究结果显示，在常规治疗基础上加用7天布地奈德混悬液雾化吸入治疗后呼吸困难评分、FEV1、FEV1/FVC、FEV1占预计值的百分比及动脉血气比较均明显优于对照组，证实布地奈德混悬液在改善AECOPD的肺功能、血气和临床症状等方面与静脉用激素效果相近，且副作用小，提示在AECOPD采用吸入激素的治疗方法是可靠安全的。
参考文献
[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南[J]中华结核和呼吸杂志,2002,25:453-460
[2]MaltaisF,OstinelliJ,TonnelAB,et al.Comparison of nebulized budesonide and oralprednisolonewithplacebo in the treatmentofacute exacerbationsof chronic obstructive pulmonary disease: a randomized controlled trial am t respire. CritCareMed,2002,165:698 - 703.
[3] Niewoehner DE,Erbland ML,Deupree RH,et al.Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.Department of Veterans Affairs Cooperative Study Group.N Engl J Med,1999,340:1941-1947
[4] Singh JM, PaldaVA, et al. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease:a systematic review. Arch Zntern Med,2002,162:2527- 2536.
[5] Mc Evoy CE,Ensrud KE,Bender E,et al.Association between corticosteroid use and vertebral fractures in olde mMen with chronic obstructive pulmonary disease. Am JRespir Crit Med,1998,157(3): 704-709.
[6] Vaghi A ,Berg E,Liljedahl S,et al. In vitro comparison of nebulised budesonide (Pulmicort Respules) and beclomethasone dipropionate (Clenil per Aerosol).Pulm Pharmacol Ther,2005,18:151-153.
[7] Szefler SJ,Lyzell E,Fitzpartrick S,et al.Safety profile of budesonide inhalation suspension in the pediatric population:worldwide experience.Ann Allergy Asthma Immunol,2004,93:83-90
本组研究结果显示，在常规治疗基础上加用7天布地奈德混悬液雾化吸入治疗后呼吸困难评分、FEV1、FEV1/FVC、FEV1占预计值的百分比及动脉血气比较均明显优于对照组，证实布地奈德混悬液在改善AECOPD的肺功能、血气和临床症状等方面与静脉用激素效果相近，且副作用小，提示在AECOPD采用吸入激素的治疗方法是可靠安全的。
参考文献
[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南[J]中华结核和呼吸杂志,2002,25:453-460
[2]MaltaisF,OstinelliJ,TonnelAB,et al.Comparison of nebulized budesonide and oralprednisolonewithplacebo in the treatmentofacute exacerbationsof chronic obstructive pulmonary disease: a randomized controlled trial am t respire. CritCareMed,2002,165:698 - 703.
[3] Niewoehner DE,Erbland ML,Deupree RH,et al.Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.Department of Veterans Affairs Cooperative Study Group.N Engl J Med,1999,340:1941-1947
[4] Singh JM, PaldaVA, et al. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease:a systematic review. Arch Zntern Med,2002,162:2527- 2536.
[5] Mc Evoy CE,Ensrud KE,Bender E,et al.Association between corticosteroid use and vertebral fractures in olde mMen with chronic obstructive pulmonary disease. Am JRespir Crit Med,1998,157(3): 704-709.
[6] Vaghi A ,Berg E,Liljedahl S,et al. In vitro comparison of nebulised budesonide (Pulmicort Respules) and beclomethasone dipropionate (Clenil per Aerosol).Pulm Pharmacol Ther,2005,18:151-153.
[7] Szefler SJ,Lyzell E,Fitzpartrick S,et al.Safety profile of budesonide inhalation suspension in the pediatric population:worldwide experience.Ann Allergy Asthma Immunol,2004,93:83-90
您现在查看是摘要介绍页，详见PDF附件(12kb)。